Yingyue Dong, Xiaozhe Sun, Hanxiao Li, Chunmiao Han, Yue Zhang, Huiru Ding, Lisha Xia, Huamin Wang, Shaomin Yang, Lingzi Xu, Guoheng Xu
BACKGROUND: Olanzapine antagonizes dopamine receptors and is prescribed to treat multiple psychiatric conditions. The main side effect of concern for olanzapine is weight gain and metabolic syndrome. Olanzapine induces hyperprolactinemia, however its effect on the mammary gland is poorly documented. METHODS: Rats received olanzapine by gavage or in drinking water at 1, 3, and 6 mg/kg/day for 5-40 days or 100 days, with and without coadministration of bromocriptine or aripiprazole and using once daily or continuous administration strategies...
March 2, 2024: Toxicology and Applied Pharmacology